The indication is based on a phase 3 trial – Empower-Lung 1 – that showed Libtayo given as a monotherapy cut the risk of death by 43% compared to chemotherapy in advanced, PD-L1-high patients ...

Libtayo plus chemotherapy increased median overall ... In the phase 3 KEYNOTE-716 trial, Keytruda improved recurrence-free survival when given to patients with high-risk advanced melanoma.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

A Jersey charity has been given an award for its work with mothers and babies. Family Nursing and Home Care's Debra Hennessy said the award from the Unicef UK Baby Friendly Initiative was "a ...

When several medications are being given at the same time, each one should be administered separately. The feeding tube should be flushed with at least 5-10 mL of water between medications.

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or excessive hair. A new artificial intelligence (AI) model designed to ...